Understand · Discuss · Plan together
Breast and Ovarian Cancer Risk in Families
A family plan should consider breast and ovarian risk separately, including the limitations of screening.
Chapter 11 of 16
Explore all 16 chapters
Family history without an identified variant
A strong breast-cancer history may justify formal risk assessment even after an uninformative negative panel. Clinician-used tools can incorporate relatives on both sides, ages and other factors. An online checklist cannot replace that assessment.
Breast surveillance
For women with BRCA1/2 pathogenic variants, a commonly used specialist approach is annual breast MRI from about 25, adding annual mammography from 30. Other high-risk categories have different starting points: ACS generally describes annual MRI plus mammography from about 30 for selected high-risk women. These are labelled international approaches, not a universal Indian screening programme. See chapter 13 for individualisation.
Ovarian risk is a different challenge
CA-125 blood testing and transvaginal ultrasound have not been shown to provide an effective mortality-reducing screening strategy for BRCA carriers. A normal test is not an assurance that ovarian cancer is absent. Persistent bloating, early fullness, pelvic pain or urinary changes require clinical assessment.
Prevention choices
For confirmed BRCA-related risk, discuss removal of both fallopian tubes and ovaries after family completion, with timing depending on BRCA1 versus BRCA2. Discuss menopause, fertility, sexual health, bone health and suitability for hormone therapy. Removing the tubes alone with delayed ovary removal remains an approach under study and is not an established equivalent.
Do not overlook men or other genes
Men can inherit and transmit these variants. Breast changes require assessment; prostate risk may also influence surveillance. PALB2, ATM, CHEK2 and other genes require their own plans. A relative’s mastectomy or ovarian surgery does not automatically mean that the same operation is appropriate for everyone.
Sources and further reading
- ACS — Breast cancer screening recommendations
- NCI PDQ — BRCA1 and BRCA2: Cancer Risks and Management
- eviQ — BRCA1 or BRCA2 risk management (female)
Accessible sources checked: 19 October 2026. International recommendations are identified where used; care in India requires individual clinical assessment. No claim is made to have directly verified restricted NCCN guidance.